Skip to main content
SpringerLink
Log in

The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients

  • Original Articles
  • Published:
Biological Trace Element Research Aims and scope Submit manuscript

Abstract

The effect of selenium (Se) in reducing the toxicity of cisplatin in cancer patients was studied. Forty-one patients were randomized into group A (20 patients with Se administration in first cycle of chemotherapy as study cases and without Se in second cycle of chemotherapy as control) and group B (21 patients without Se in first cycle of chemotherapy and with Se in second cycle of chemotherapy). The 400 μg per day of Se as Seleno-Kappacarrageenan were administered from 4 before to 4 d after chemotherapy for study cases. The serum Se increased from 70.4±22.86 to 157.04±60.23 ng/mL (P<0.001) in patients received Se. The cisplatin dosage was iv administration in 60–80 mg/m2 on the first day. The results showed that the peripheral WBC counts on day 14 after initiation of chemotherapy in study cases was significantly higher than the controls (3.35±2.01 vs 2.31±1.38 [×109L])/L,p<0.05). On the other hand, the consumption of GCSF for the cases was significantly less than the controls (110.1±82.2 vs 723.6±192.6 IU,p<0.05). The volumes of blood transfusion for the study group were also significantly less than the controls (0 vs 62±38mL,p<0.05). The nephrotoxicity of cisplatin was measured by urine enzymes (NAG, GGT, AAP, LAP, and ALP) were determined prior to and at 2, 24, 48, and 72h after initiation of chemotherapy. The urine enzymes NAG, GGT, AAP, and ALP after chemotherapy for cases were significantly lower than the controls. No toxicity of Seleno-Kappacarrageenan was noted. The above results suggest that the Se can be used as an agent for reducing the nephrotoxicity and bone marrow suppression induced by cisplatin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. A. W. Prestayko, S. T. Crooke, and S. K. Carter, eds.Cis-platin: Current Status and New Developments. Academic, New York (1980).

    Google Scholar 

  2. T. P. Luckey and B. Wenugopol,Metal Toxicity in Mammals, vol. 2. Elsevier/North-Holland, Amsterdam (1977).

    Google Scholar 

  3. I. H. Krakoff, Nephrotoxicity of cis-dichlorodiammineplatinum (II),Cancer Treat. Rep. 63, 1523–1525 (1979).

    PubMed  CAS  Google Scholar 

  4. E. M. Walker and G. R. Gale, Methods of reduction of cis-platin nephrotoxicity,Ann. Clin. Lab. Sci. 11, 397–410 (1981).

    PubMed  CAS  Google Scholar 

  5. W. C. Rose and J. E. Schurig, Preclinical antitumor and toxicological profile of carboplatin,Cancer. Treat. Rep. 12 (suppl. A), 1–9 (1985).

    Article  CAS  Google Scholar 

  6. R. F. Ozols, B. J. Cordon, J. Jacob, M. N. Wesley, Y. Ostehega, and R. C. Young, High-dose cis-platin in hypertonic saline,Ann. Inter. Med. 100, 19–24 (1984).

    CAS  Google Scholar 

  7. C. E. Pfeifle, S. B. Howell, R. D. Felthouse, T. B. Woliver, P. A. Andrews, M. Markman, and M. P. Murphy, High dose-cis-platin with sodium thiosulfate protection,J. Clin. Oncol. 3, 237–244 (1987).

    Google Scholar 

  8. D. L. Bodenner, P. C. Dedon, J. C. Katz, and R. F. Borch, Selective protection against cis-diamminedichloroplatinum (II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate,Cancer. Res. 46, 2751–2755 (1986).

    PubMed  CAS  Google Scholar 

  9. M. L. Rothenberg, Y. Ostchega, S. M. Steinberg, R. C. Young, S. Hummel, and R. F. Ozols, High-dose carboplatin with diethyldithiocarbamate chemoprotection in treatment of women with relapsed ovarian cancer,J. Natl. Cancer Inst. 80, 1488–1492 (1988).

    Article  PubMed  CAS  Google Scholar 

  10. M. Satoh, A. Naganuma, N. Imura. Deficiency of selenium intake enhances manifestation of renal toxicity of cis-diamminedichloroplatinum in mice,Toxicol. Lett. 38(1–2), 155–160 (1987).

    PubMed  CAS  Google Scholar 

  11. L. N. Vernie, J. J. de-Goeij, C. Zeger, M. Devries, G. S. Baldew, and J. G. Mevie. Cisplatin-induced changes of selenium levels and glutathione peroxidase activities in blood of testis tumor patients,Cancer. lett 40(1), 83–91 (1988).

    Article  PubMed  CAS  Google Scholar 

  12. V. R. Young, Selenium: a case for its essentiality in man,N. Engl. J. Med. 304, 1228 (1981).

    Article  PubMed  CAS  Google Scholar 

  13. R. J. Shamberger and D. V. Frost, Possible protective effect of selenium against human cancer,Can. Med. Ass. J. 103, 682 (1969).

    Google Scholar 

  14. Y. J. Chu, Q. Y. Liu, C. Hou, and S. Y. Yu, Blood selenium concentration in residents of areas in China having a high incidence of lung cancer,Biol Trace Element Res. 6(2), 133–137 (1984).

    CAS  Google Scholar 

  15. W. Willett, B. F. Polk, S. Morris, M. J. Stampfer, S. Pressel, B. Rosnern, J. O. Taylor, K. Schneider, and C. G. Hames, Prediagnostic serum selenium and risk of cancer,Lancet 2, 130–134 (1983).

    Article  PubMed  CAS  Google Scholar 

  16. P. Knekt, A. Aromaa, L. Maateta, et al. Serum selenium and subsequent risk of cancer among Finnish men and woman.J. Nat. Cancer. Inst. 82(10), 846–848 (1990).

    Article  Google Scholar 

  17. K. P. McConnell, W. L. Broghamer, A. J. Blotcky, Selenium levels in human blood and tissue in health and disease,J. Nutr. 105, 1026–1031 (1975).

    PubMed  CAS  Google Scholar 

  18. Y. J. Hu, Y. N. Zhao, P. M. Xu, S. D. Yang, Y. W. Lin, and J. H. Wu, A study of blood selenium levels in patients with lung cancer and healthy subjects in Beijing area,Acta Nutrimenta. Sinica. 16(3), 261–264 (1994).

    Google Scholar 

  19. C. Ip. Factors influencing the anticarcinogenic efficacy of selenium in dimethylbenz (a)anthracene-induced mammary tumorigenesis in rats,Cancer Res. 41, 2683–2686 (1981).

    PubMed  CAS  Google Scholar 

  20. C. Ip, M. M. Ip, and U. Kim, Dietary selenium intake and growth of MT-W9B transplantable rat mammary tumor,Cancer Lett. 14, 101–107 (1981).

    Article  PubMed  CAS  Google Scholar 

  21. G. Hocman, Chemoprevention of cancer: selenium,Int. J. Biochem. 20(2), 123–132 (1988).

    Article  PubMed  CAS  Google Scholar 

  22. A. M. Watrach, J. A. Milner, M. A. Watrach, and K. A. Poirier, Inhibition of human breast cancer cells by selenium,Cancer Lett 25(1), 41–47 (1984).

    Article  PubMed  CAS  Google Scholar 

  23. S. Y. Yu, Y. J. Chu, W. G. Li, Q. S. Huang, C. Z. Huang, Q. N. Zhang, and C. Hou, A preliminary report on the intervention trials of primary liver cancer in high risk populations with nutritional supplementation of selenium in China,Biol. Trace Elements Res. 29, 289–294 (1991).

    Article  CAS  Google Scholar 

  24. W. L. Blot, J. Y. Li, P. R. Taylor, et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population,J. Natl. Cancer. Inst. 85(18), 1483–1492 (1993).

    Article  PubMed  CAS  Google Scholar 

  25. A. Naganuma, M. Satoh, M. Yokoyama, and N. Imura, Selenium efficiently depressed toxic side effect of cis-diamminedichloroplatinum,Res. Commun Chem. Pathol. Pharmacol. 42(1), 127–134 (1983).

    PubMed  CAS  Google Scholar 

  26. J. P. Berry, C. Pauwells, S. Tlouzeau, and G. Lespinats, Effect of selenium in combination with cis-diamminedichloroplatinum(II) in the treatment of murine fibrosarcoma,Cancer. Res. 44(7), 2864–2868 (1984).

    PubMed  CAS  Google Scholar 

  27. M. Yokoyama, A. Naganuma and N. Imura, Suppression of CDDP-induced renal toxicity by sodium selenite,Gan. No. Rinsho. (Japanese)31(9 Suppl), 1225–1230 (1985).

    CAS  Google Scholar 

  28. K. Ohkawa, Y. Tsukada, and H. Dohzono, K. Koike, and Y. Terashima, The effects of co-administration of selenium and cis-platin (CDDP) on CDDP-induced toxicity and antitumour activity,Br. J. Cancer. 58(10) 38–41 (1988).

    PubMed  CAS  Google Scholar 

  29. G. S. Baldew, C. J. Van-den Hamer, G. Los, N. P. E. Vermeulen, J. J. M. de Goeij, and J. G. Mevie, Selenium-induced protection against cis-diamminedichloroplatinum (II) nephrotoxicity in mice and rats,Cancer. Res. 49(11), 3020–3023 (1989).

    PubMed  CAS  Google Scholar 

  30. G. S. Baldew, J. G. McVie, M. A. Van-der-valk, G. Los, J. J. de Goeij, and N. P. E. Vermeulen, Selective reduction of cis-diammindichloroplatinum(II) nephrotoxicity by ebselen,Cancer. Res. 50(21), 7031–7036 (1990).

    PubMed  CAS  Google Scholar 

  31. Y. Araya, Studies on protective effect of selenium on the nephrotoxicity of cisdiamminedichloroplatinum (CDDP) in mice,Hokkaido. Igoaku. Zasshi. 65(3), 245–253 (1990).

    CAS  Google Scholar 

  32. M. Satoh, A. Naganuma, and N. Imura, Optimum schedule of selenium administration to reduce lethal and renal toxicities of cis-diamminedichloroplatinum (cis-DDP) in mice,J. Pharmacobiodyn. 12(4), 246–253 (1989).

    PubMed  CAS  Google Scholar 

  33. B. Leyland Jones, C. Morrow, S. Tate, C. Urmacher, C. Gordon, and C. W. Young, Cisdiamminedichloroplatinum(II) nephrotoxicity and Its relationship to renal to gammaglutamyl transpeptidase and glutathione,Cancer. Res,43(12 pt 1), 6072–6076 (1983).

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Beijing Hospital, 100730, P.R. China

    Ya-Jun Hu, Yan Chen, Yong-Qiang Zhang, Mei-Zhen Zhou, Bao-Zhu Zhang, Pei-Min Xu, Yi-Niam Zhao, Yun-Bo Zhao & Gang Cheng

  2. Department of Biochemistry, Beijing Hospital, P.R. China

    Ling Luo

  3. Beijing Tian Ci Fu Medical Biology Company, 100730, P.R. China

    Xue-Mei Song

Authors
  1. Ya-Jun Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yan Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yong-Qiang Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mei-Zhen Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xue-Mei Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Bao-Zhu Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ling Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Pei-Min Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yi-Niam Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yun-Bo Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Gang Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hu, YJ., Chen, Y., Zhang, YQ. et al. The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients. Biol Trace Elem Res 56, 331–341 (1997). https://doi.org/10.1007/BF02785304

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02785304

Index Entries

Search

Navigation